NGeneBio Launches NGS Analysis Software 'NGAS 2.0'... Kicks Off Paid Business Expansion

Transition to Web-Based Platform, Advanced Variant Information
Paid Supply to Hospitals and Testing Institutions

On September 21, NGeneBio announced the official launch of its next-generation sequencing (NGS) gene panel test software ‘NGeneAnalySys (NGAS) 2.0’ and the full-scale rollout of its paid supply to hospitals and testing institutions both domestically and internationally.

User review screen of NGeneBio's NGS analysis software ‘NGAS 2.0’. NGeneBio

NGAS 2.0 enhances the functions of the previous analysis software while introducing paid access to the latest variant databases and a subscription-based business model. The company plans to encourage current NGAS users and institutions that have adopted precision diagnostic panels to migrate to the new version, aiming to expand both software and data revenue.

NGAS is software designed to support the analysis of sequencing data generated from NGS tests, variant detection, clinical interpretation, and the creation of test result reports. NGAS 2.0 adopts a web-based architecture to reduce the burden of installing and maintaining separate programs. It also allows users to perform essential analysis work even in closed networks with restricted internet access.

The variant interpretation features have also been strengthened. By shortening the update cycle of its annotation database, the software provides the most up-to-date variant information and clinical evidence. In addition, integration with external databases enables the verification of the clinical significance of variants and therapy-related evidence.

The review and statistics functions have also been upgraded. Users can search for the history of previous identical or similar variant interpretations and extract accumulated test results as statistical data according to various conditions. This functionality is intended not just for test operations, but also for submitting data within hospitals and supporting clinical research by medical professionals.

Currently, NGAS is used in more than 30 hospitals in Korea, including Asan Medical Center, Seoul National University Hospital, Seoul St. Mary’s Hospital of The Catholic University of Korea, and Soonchunhyang University Hospital. NGeneBio plans to leverage its existing client base to accelerate the adoption of NGAS 2.0.

Looking ahead, NGeneBio intends to expand support to cover not only its own cancer precision diagnostic panels but also external NGS panels such as Illumina’s TSO 500 and Thermo Fisher Scientific’s Oncomine. This expansion aims to position NGAS 2.0 as a stand-alone software solution applicable in various testing environments.

Kyungnam Lee, CEO of NGeneBio, stated, “NGAS 2.0 is a next-generation platform that upgrades every step of NGS laboratory work—including analysis, interpretation, review, and report generation—from the actual user’s perspective. Based on our existing hospital clientele and user base, we will drive the adoption and paid supply of version 2.0, establishing a business structure in which both the precision diagnostic panels and the software grow together.”

This content was produced with the assistance of AI translation services.